Latest News

Search News
Categories
Archives
Immune cells assemble – boosting the effects of chemotherapy in pancreatic cancer

9th July 2021

A new study from Barts Cancer Institute, Queen Mary University of London, has demonstrated that immune cells can be stimulated to assemble into special structures within pancreatic cancer such that, at least in a pre-clinical model, researchers can demonstrate an improvement in the efficacy of chemotherapy.

Read more

Doctoral training programme secures future investment from MRC

8th July 2021

A partnership between Queen Mary University of London and the University of Southampton has successfully bid for 45 studentships from the Medical Research Council (MRC), part of UK Research and Innovation (UKRI).

Read more

Study identifies biomarker that could help to diagnose pancreatic cancer

29th June 2021

Researchers from Barts Cancer Institute, Queen Mary University of London, have identified a protein that could be used to aid in the diagnosis of pancreatic cancer. Findings from the new study suggest that a protein called pentraxin 3 may be a specific diagnostic biomarker – or biological measure – for pancreatic cancer, with the ability to differentiate pancreatic cancer from other non-cancerous conditions of the pancreas.

Read more

BCI researcher part of team shortlisted for Cancer Grand Challenges awards

23rd June 2021

Dr Benjamin Werner from Barts Cancer Institute, Queen Mary University of London, is part of an international team that has been selected to share its ideas on how to solve one of cancer’s toughest challenges.

Read more

BCI academic receives prestigious science learning award

17th June 2021

Congratulations to Professor Fran Balkwill from Barts Cancer Institute, Queen Mary University of London, who has been announced as the 2021 winner of the Beetlestone Award, which recognises leadership and legacy in the field of informal science learning.

Read more

Study suggests blood test could guide precision treatment in bladder cancer

16th June 2021

A blood test that can detect tiny amounts of circulating cancer DNA may be able to identify risk of cancer recurrence and guide precision treatment in bladder cancer following surgery, according to a clinical study led by Professor Tom Powles from Barts Cancer Institute at Queen Mary University of London and Barts Health NHS Trust. The findings from the study, published today in Nature, may change our understanding of cancer care following surgery.

Read more

Search News
Categories
Archives
© 2013 ~ 2022 Cancer Research UK Barts Centre